Chris Cumming

3 weeks ago | wsj.com | Chris Cumming |Luis Garcia |Luis García

Two federal courts made contradictory decisions on lawsuits claiming Apollo Global Management’s insurer Athene is too risky to manage pension assetsApril 2, 2025 6:00 am ET|WSJ ProFor the past year, the insurance industry has been on edge over a series of class-action lawsuits arguing that Athene Holding, an insurer tied to private-markets giant Apollo Global Management, is too risky to be part of America’s retirement system.

1 month ago | wsj.com | Chris Cumming

U.S. authorities are investigating potential fraud in the 2022 sale of software business Mobileum, court papers show, raising the stakes of a legal fight between private-equity firms H.I.G. Capital and Audax over a deal in which each firm has accused the other of misdeeds. H.I.G. Capital and Audax are suing each other in Delaware over Mobileum, a telecommunications-software business H.I.G acquired in 2022 and that filed for bankruptcy last year.

1 month ago | wsj.com | Chris Cumming

The new leadership in Washington has declared plans to fulfill a longtime policy goal for private-equity managers: expanding the pool of ordinary people who can invest in the asset class. In a speech last week, the acting chair of the Securities and Exchange Commission, Mark Uyeda, announced a firm break with Biden administration policy and said he was seeking ways to open private markets to so-called retail investors. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved.

2 months ago | wsj.com | Chris Cumming

At $16 billion including co-investments and related vehicles, Oaktree Opportunities Fund XII edges out the $15.9 billion predecessor, which closed in 2021, as the largest in the Los Angeles firm’s history as well as the largest distressed-debt fund ever raised, according to PitchBook Data, which tracks data on private markets. The new fund is also the fifth-largest private debt fund ever raised globally, behind four direct-lending vehicles, PitchBook’s data show.

2 months ago | wsj.com | Chris Cumming

ArchiMed has agreed to sell in vitro diagnostics company Diesse Diagnostica Senese in a deal that will produce a sizable profit for the European private-equity firm and its investors. ArchiMed has finalized a pact to sell Diesse to fellow private-equity firm Fremman Capital at an enterprise value of about €125 million, or roughly $131 million, said Denis Ribon, chairman and managing partner of ArchiMed. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8